ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Damage Index"

  • Abstract Number: 2346 • ACR Convergence 2023

    SLE Medication Usage and Organ Damage Among Adult SLE Patients with SLE Treated with Belimumab (BEL): Pooled Data from Three Open-Label Extension Studies over 11+ Years

    Zahi Touma1, Cristina Arriens2, Christine Henning3, Angela Carroll3, Paula Curtis4, Roger A. Levy5 and William Stohl6, 1University of Toronto, Toronto, ON, Canada, 2Oklahoma Medical Research Foundation and University of Oklahoma Health Sciences Center, Department of Arthritis & Clinical Immunology, Oklahoma City, OK, 3GlaxoSmithKline, US Medical Affairs, Durham, NC, 4GlaxoSmithKline, R&D Biostatistics, Brentford, United Kingdom, 5GlaxoSmithKline, Global Medical Affairs, Collegeville, PA, 6University of Southern California Keck School of Medicine, Division of Rheumatology, Los Angeles, CA

    Background/Purpose: A key treatment goal for patients (pts) with SLE is to reduce use of CS, due to their association with organ damage.1 BEL is…
  • Abstract Number: 2553 • ACR Convergence 2023

    Prevalence, Determinants and Outcomes of Target Attainment in SLE Patients with Clinically Active Disease in a Large Multinational Prospective Lupus Cohort

    Yanjie Hao1, Dylan Hansen2, Rangi Kandane-Rathnayake3, Worawit Louthrenoo4, Yi-Hsing Chen5, Jiacai Cho6, Aisha Lateef6, Laniyati Hamijoyo7, Shue-Fen Luo8, Yeong-Jian J Wu9, Sandra Navarra10, Leonid Zamora10, Zhanguo Li11, Sargunan Sockalingam12, Yasuhiro Katsumata13, Masayoshi Harigai13, Zhuoli Zhang14, Madelynn Chan15, Jun Kikuchi16, Tsutomu Takeuchi17, Sang-Cheol Bae18, Fiona Goldblatt19, Sean O’Neill20, Kristine Ng21, Annie Law22, BMDB Basnayake23, Nicola Tugnet24, Sunil Kumar25, Cherica Tee26, Michael Tee26, Yoshiya Tanaka27, Chak Sing Lau28, Vera Golder3, Alberta Hoi29, Eric Morand30, Shereen Oon31 and Mandana Nikpour32, 1The University of Melbourne Department of Medicine at St Vincents Hospital Melbourne, Melbourne, Australia, 2Department of Rheumatology, St Vincent’s Hospital Melbourne, Fitzroy, Australia, 3Monash University, Department of Medicine, Sub-faculty of Clinical and Molecular Medicine, Clayton, Australia, 4Chiang Mai University Hospital, Department of Internal Medicine, Faculty of Medicine, Chiang Mai, Thailand, 5Division of Allergy, Immunology and Rheumatology, Taichung Veterans General Hospital, Taichung, Taiwan, 6National University Hospital, Rheumatology Division, Department of Medicine, Singapore, Singapore, 7Padjadjaran University/Hasan Sadikin General Hospital, Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Bandung, Indonesia, 8Chang Gung University, Department of Rheumatology, Allergy and Immunology, Chang Gung Memorial Hospital, Taoyuan, Taiwan, 9Chang Gung University, Department of Rheumatology, Allergy and Immunology, Chang Gung Memorial Hospital, Keelung, Taiwan, 10University of Santo Tomas Hospital, Joint and Bone Center, Manila, Philippines, 11Peking University Health Science Center, Department of Rheumatology and Immunology, People's Hospital, Beijing, China, 12University of Malaya, Department of Medicine, Faculty of Medicine Building, Kuala Lumpur, Malaysia, 13Tokyo Women's Medical University, Division of Rheumatology, Department of Internal Medicine, Tokyo, Japan, 14Peking University First Hospital, Rheumatology and Immunology Department, Beijing, China, 15Tan Tock Seng Hospital, Department of Rheumatology, Allergy & Immunology, Singapore, Singapore, 16Keio University School of Medicine, Tokyo, Japan, 17Keio University School of Medicine and Saitama Medical University, Tokyo, Japan, 18Hanyang University Hospital for Rheumatic Diseases and Hanyang University Institute for Rheumatology Research, Department of Rheumatology, Seoul, South Korea, 19Royal Adelaide Hospital and Flinders Medical Centre, Adelaide, Australia, 20Department of Medicine, University of New South Wales, Kensington, Australia, 21Waitemata DHB, Auckland, New Zealand, 22Singapore General Hospital; Duke-NUS Medical School, Singapore, Singapore, 23Division of Nephrology, Teaching Hospital Kandy, Adelaide, Australia, 24Auckland District Health Board, Auckland, New Zealand, 25Middlemore Hospital, Auckland, New Zealand, 26University of the Philippines, Manila, Philippines, 27University of Occupational and Environmental Health, Kitakyushu, Japan, 28University of Hong Kong, Division of Rheumatology & Clinical Immunology, Department of Medicine, Queen Mary Hospital, Hong Kong, Hong Kong, 29Monash University, Department of Medicine, Sub-faculty of Clinical and Molecular Medicine, Melbourne, Australia, 30Monash University, Centre for Inflammatory Diseases, Melbourne, Australia, 31University of Melbourne at St Vincent’s Hospital, Departments of Rheumatology and Medicine, Fitzroy, Australia, 32The University of Melbourne at St. Vincent’s Hospital Melbourne, Departments of Medicine and Rheumatology, Melbourne, Australia

    Background/Purpose: There is increasing interest in adopting the principle of treating to target (T2T) in systemic lupus erythematosus (SLE). Remission and low disease activity states…
  • Abstract Number: 2559 • ACR Convergence 2023

    Clinical Manifestations and Immunomodulatory Treatment in Patients with Relapsing Polychondritis

    Roger Yang1, Rennie Rhee2, Kaitlin Quinn3, Naomi Amudala2, Peter Grayson4, Peter Merkel2, Marcela Ferrada5 and Shubhasree Banerjee2, 1University of Pennsylvania, Montréal, QC, Canada, 2University of Pennsylvania, Philadelphia, PA, 3National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, 4National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Chevy Chase, MD, 5NIH, Bethesda, MD

    Background/Purpose: Relapsing polychondritis (RP) is a rare systemic inflammatory disease without standard treatment guidelines. This study aims to investigate the clinical characteristics, current treatment approaches,…
  • Abstract Number: PP17 • ACR Convergence 2022

    Engaging with the Spoon Theory: How I Make Decisions Using a Cost-Benefit Analysis That Works to Improve My Mental Health While Living with RA

    Stephanie Aleite, AiArthritis, St. Louis, MO

    Background/Purpose: Patients living with rheumatoid arthritis (RA) often also live with comorbid mental health conditions. Regardless of diagnosed mental health condition, living with a chronic…
  • Abstract Number: 0098 • ACR Convergence 2022

    Delays in Access to Specialized Care and Diagnosis in Patients with Systemic Lupus Erythematosus

    Alain Sanchez-Rodriguez1, Jose A Meade-Aguilar2, Jeffrey X. Yang2, Gabriel Figueroa Parra2, Shirley-Ann Osei-Onomah2, Rachel Giblon3, Hannah Langenfeld4, Alanna Chamberlain2, Cynthia Crowson5 and Ali Duarte-Garcia2, 1Division of Rheumatology, Mayo Clinic, Rochester, MN, 2Mayo Clinic, Rochester, MN, 3Mayo Clinic, Rochester, MN, Rochester, MN, 4Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, 5Mayo Clinic, Eyota, MN

    Background/Purpose: Delays in access to specialized care and diagnosis of systemic lupus erythematosus (SLE) are associated with poor outcomes. Prior studies rely mostly on cross-sectional…
  • Abstract Number: 0160 • ACR Convergence 2022

    Sarcopenia in Myositis Patients: A Marker of Muscle Damage Associated with Myositis Severity and Disability

    Margherita Giannini1, Léa Debrut2, Anne-Laure Charles2, Mégane Pizzimenti2, Rose-Marie Javier3, Bernard Geny4 and Alain Meyer1, 1Service de Physiologie et explorations fonctionnelles, CHU, Strasbourg ; Centre de Référence des Maladies Autoimmunes Rares, CHU, Strasbourg ; UR3072, Centre de Recherche en Biomédecine, University of Strasbourg, Strasbourg, France, 2UR3072 Centre de Recherche en Biomédecine, University of Strasbourg, Strasbourg, France, 3Service de Rhumatologie, Centre de Référence des Maladies Autoimmunes Rares, University Hospital of Strasbourg, Strasbourg, France, 4Service de Physiologie et explorations fonctionnelles, CHU, Strasbourg ; UR3072 Centre de Recherche en Biomédecine, University of Strasbourg, Strasbourg, France

    Background/Purpose: Myositis are autoimmune diseases characterized by muscle inflammation and weakness. Even when disease is no longer active, a great proportion of patients does not…
  • Abstract Number: 0343 • ACR Convergence 2022

    Severe Non-adherence to Hydroxychloroquine Is Associated with Flares, Early Damage, and Mortality in Systemic Lupus Erythematosus: Data from 660 Patients from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort

    Yann Nguyen1, Benoît BLanchet2, Murray Urowitz3, John Hanly4, Caroline Gordon5, Sang-Cheol Bae6, Juanita Romero-Diaz7, Jorge Sanchez-Guerrero8, Ann E Clarke9, Sasha Bernatsky10, Daniel Wallace11, David Isenberg12, Anisur Rahman13, Joan Merrill14, Paul R Fortin15, Dafna Gladman16, Ian N. Bruce17, Michelle Petri18, Ellen M. Ginzler19, Mary Anne Dooley20, Rosalind Ramsey-Goldman21, Susan Manzi22, Andreas Jönsen23, Graciela Alarcón24, Ronald van Vollenhoven25, Cynthia Aranow26, Veronique Le Guern27, Meggan Mackay26, Guillermo Ruiz-Irastorza28, S. Sam Lim29, Murat Inanc30, Kenneth C Kalunian31, Soren Jacobsen32, Christine Peschken33, Diane Kamen34, Anca Askanase35, Jill Buyon36 and Nathalie Costedoat-Chalumeau37, 1AP-HP.Centre Universit Paris Cit Hôpital Cochin, Montmorency, France, 2Biologie du médicament-Toxicologie, AP-HP Centre – Hôpital Cochin, Université Paris Cité, Paris, France, Paris, 3University of Toronto, University Health Network, Schroeder Arthritis Institute, Toronto, ON, Canada, 4Division of Rheumatology, Queen Elizabeth II Health Sciences Center (Nova Scotia Rehabilitation Site) and Dalhousie University, Halifax, NS, Canada, 5Rheumatology Research Group, Institute of Inflammation and Ageing, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom, 6Hanyang University Medical Center, Seoul, Republic of Korea, 7Instituto Nacional de Ciencias Medicas y Nutricion SZ, Ciudad de México, Mexico, 8Mount Sinai Hospital and University Health Network, University of Toronto, Toronto, ON, Canada, 9University of Calgary, Division of Rheumatology, Cumming School of Medicine, Calgary, AB, Canada, 10Research Institute of the McGill University Health Centre, Montréal, QC, Canada, 11Cedars-Sinai Medical Center, Los Angeles, CA, 12University College London, London, United Kingdom, 13Centre for Rheumatology, Department of Medicine, University College London, London, United Kingdom, 14Oklahoma Medical Research Foundation, Oklahoma City, OK, 15Centre ARThrite - CHU de Québec - Université Laval, Québec, QC, Canada, 16Toronto Western Hospital, Schroeder Arthritis Institute, Toronto, ON, Canada, 17Centre for Epidemiology Versus Arthritis, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, United Kingdom, 18Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD, 19SUNY Downstate Health Sciences University, Department of Medicine, Brooklyn, NY, 20Thurston Arthritis Research Center, University of North Carolina, Chapel Hill, NC, 21Northwestern University Feinberg School of Medicine, Chicago, USA, Chicago, IL, 22Allegheny Health Network, Lupus Center of Excellence, Wexford, PA, 23Lund University, Lund, Sweden, 24The University of Alabama at Birmingham, Oakland, 25Amsterdam University Medical Centers, Amsterdam, Netherlands, 26Feinstein Institutes for Medical Research, Manhasset, NY, 27Hôpital Cochin, Paris, France, 28Autoimmune Diseases Research Unit, Biocruces Bizkaia Health Research Institute, Hospital Universitario Cruces, UPV/EHU, Barakaldo, Spain, 29Emory University, Atlanta, GA, 30Division of Rheumatology, Department of Internal Medicine, Istanbul Medical Faculty, Istanbul University, Istambul, Turkey, 31University of California San Diego School of Medicine, La Jolla, 32Rigshospitalet, Copenhagen, Denmark, 33University of Manitoba, Winnipeg, MB, Canada, 34Medical University of South Carolina, Charleston, SC, 35Columbia University Medical Center, New York, NY, 36NYU Grossman School of Medicine, New York, NY, 37Inserm DR Paris 5, Paris, France

    Background/Purpose: The efficacy of antimalarials, especially hydroxychloroquine (HCQ), in preventing flares of systemic lupus erythematosus (SLE) is well demonstrated, but its effectiveness is impaired by…
  • Abstract Number: 0541 • ACR Convergence 2022

    Prevalence of Venous Thrombo-Embolism in Lupus Nephritis and Associated Risk Factors

    Tara Tofighi, Jiandong Su and Zahi Touma, Schroeder Arthritis Institute, Krembil Research Institute, University Health Network and University of Toronto, Toronto, ON, Canada

    Background/Purpose: Patients with SLE have an increased risk of developing venous thrombo-embolism (VTE) based on several cohort studies, accounting for significant morbidity and mortality. Lupus…
  • Abstract Number: 0677 • ACR Convergence 2022

    Obstructive Sleep Apnea in Primary Antiphospholipid Syndrome Impacts Damage Accrual

    Gustavo Balbi1, Flavio Victor Signorelli2, Ana Paula Gandara3, Indira Azam3, Dilson Marreiros3, Luciano Drager3 and Danieli Castro Oliveira de Andrade4, 1Universidade de São Paulo, São Paulo, Brazil, 2Universidade do Estado do Rio de Janeiro, Rio De Janeiro, Brazil, 3University of São Paulo, São Paulo, Brazil, 4Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil

    Background/Purpose: Obstructive sleep apnea (OSA) has been associated with an increased risk of thrombotic-related events, such as myocardial infarction and cerebrovascular diseases in the general…
  • Abstract Number: 0982 • ACR Convergence 2022

    Effect of Cumulative Hydroxychloroquine Dose on Prevention of Damage Progression and Cardiovascular Events in Patients with Systemic Lupus Erythematosus

    Jordan Jacquez1, Lisa Zhu1, Manpreet Singh1, Caroline Siegel2, Lori Sahakian1, Brian Skaggs1, Jennifer Grossman1 and Maureen McMahon1, 1University of California Los Angeles, Los Angeles, CA, 2Hospital for Special Surgery, New York, NY

    Background/Purpose: Hydroxychloroquine (HCQ) has demonstrated benefit in multiple outcomes in systemic lupus erythematosus (SLE), including disease activity, flare rates, survival, and thrombotic events. Previous studies,…
  • Abstract Number: 1528 • ACR Convergence 2022

    Nintedanib in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) and Organ Damage: Data from the SENSCIS Trial

    Janet Pope1, Susanna Proudman2, Wendy Stevens3, Joerg Henes4, Rozeta Simonovska5, Margarida Alves6 and Yannick Allanore7, 1University of Western Ontario, London, ON, Canada, 2Rheumatology Unit, Royal Adelaide Hospital, and Discipline of Medicine, University of Adelaide, Adelaide, Australia, 3Department of Rheumatology, St Vincent’s Hospital, Melbourne, Australia, Melbourne, Australia, 4Center for Interdisciplinary Clinical Immunology, Rheumatology and Auto-inflammatory Diseases (INDIRA), University Hospital Tübingen, Tübingen, Germany, 5mainanalytics GmbH, Sulzbach (Taunus), Germany, Sulzbach (Taunus), Germany, 6Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, 7Department of Rheumatology A, Descartes University, APHP, Cochin Hospital, Paris, France, Paris, France

    Background/Purpose: The Scleroderma Clinical Trials Consortium Damage Index (SCTC-DI) was developed to quantify organ damage in patients with SSc. We assessed outcomes in the SENSCIS…
  • Abstract Number: 1562 • ACR Convergence 2022

    Validation of Behçet’s Disease Overall Damage Index (BODI) for Retrospective Studies and a Proposal for Modification

    Yeliz Yagiz Ozogul1, Yesim Ozguler2, Didar Ucar3, Ugur Uygunoglu4, Zekayi Kutlubay5, Vedat Hamuryudan6 and gulen Hatemi7, 1Istanbul University-Cerrahpaşa, Cerrahpaşa Medical School, Department of Internal Medicine, Istanbul, Turkey, 2Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, New York, NY, 3Istanbul University-Cerrahpaşa, Cerrahpaşa Medical School, Department of Ophthalmology, Istanbul, Turkey, 4Istanbul University-Cerrahpaşa, Cerrahpaşa Medical School, Department of Neurology, Istanbul, Turkey, 5Istanbul University-Cerrahpaşa, Cerrahpaşa Medical School, Department of Dermatology, Istanbul, Turkey, 6Istanbul University-Cerrahpaşa, Cerrahpaşa Medical School, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, 7Istanbul University-Cerrahpaşa, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey

    Background/Purpose: Damage accrual in Behçet syndrome (BS) may progress over the years and an index that can be scored using retrospective data may be useful…
  • Abstract Number: 1602 • ACR Convergence 2022

    Fibroblast Activation Protein (FAP) PET-CT for Depicting Inflammatory Joint Damage in Patients with Psoriatic Arthritis

    Simon Rauber1, Hashem Mohammadian2, Chrstian Schmidkonz3, Armin Atzinger3, Maria Gabriella Raimondo1, Hannah Labinsky4, Christoph Treutlein2, Johannes Knitza1, Simone Maschauer2, Frank Roemer5, Olaf Prante2, Torsten Kuwert3, Juan Canete6, Georg Schett7 and Andreas Ramming1, 1Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg and Universitätsklinikum Erlangen, 91054 Erlangen, Germany; Deutsches Zentrum Immuntherapie, Friedrich-Alexander-UniversityErlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, 2Friedrich-Alexander-University (FAU) Erlangen-Nürnberg, Erlangen, Germany, 3Friedrich-Alexander University (FAU) Erlangen-Nuremberg, Erlangen, Germany, 4Department of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg and Universitätsklinikum Erlangen, 91054 Erlangen, Germany; Deutsches Zentrum Immuntherapie, Friedrich-Alexander-University Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, 5Friedrich-Alexander University Erlangen Nürnberg, Erlangen, Germany, 6Unidad de Artritis Hospital Clinic, Barcelona, Spain, 7Universitätsklinikum Erlangen, Erlangen, Germany

    Background/Purpose: Psoriatic arthritis (PsA) is characterized by substantial mesenchymal tissue activation in the context of inflammation leading to structural damage. Measuring mesenchymal tissue activation in…
  • Abstract Number: 1877 • ACR Convergence 2022

    Nailfold Videocapillaroscopic Abnormalities Correlate with Disease Activity Measures and Cutaneous Damage in Patients with Idiopathic Inflammatory Myopathies

    Diane Zisa1, Aliza Bloostein1, Deanna Jannat-Khah, DrPH, MSPH1, Maurizio Cutolo2, Vanessa Smith3 and David Fernandez1, 1Hospital for Special Surgery, New York, NY, 2Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS San Martino Polyclinic Hospital, Genova, Italy, 3Department of Rheumatology, Ghent University Hospital – Department of Internal Medicine, Ghent University, Belgium – Unit for Molecular Immunology and Inflammation, VIB Inflammation Research Center (IRC), Gent, Belgium

    Background/Purpose: Nailfold videocapillaroscopy (NVC) is a non-invasive tool used to evaluate the microcirculation of patients with connective tissue diseases (CTDs). A specific combination of NVC…
  • Abstract Number: 2067 • ACR Convergence 2022

    Predictors of Organ Damage Accrual by Domains

    Rangi Kandane-Rathnayake1, Ning Li1, Vera Golder1, Worawit Louthrenoo2, Yi-Hsin Chen3, Jiacai Cho4, Aisha Lateef5, Laniyati Hamijoyo6, Luo Shue Fen7, Yeong-Jian Wu7, Sandra Navarra8, Leonid Zamora9, Zhanguo Li10, An Yuan11, Sargunan Sockalingam12, Yasuhiro Katsumata13, Masayoshi Harigai13, Yanjie Hao14, Zhouli Zhang15, Madelynn Chan16, Jun Kikuchi17, Tsutomu Takeuchi18, Shereen Oon19, Sang-Cheol Bae20, Fiona Goldblatt21, Sean O'Neill22, Kathy Gibson22, Kristine Ng23, Hui Nee Annie Law24, Duminda Basnayake25, Nicole Tugnet26, Sunil Kumar27, Cherica Tee28, Michael Tee28, Yoshiya Tanaka29, Chak Sing30, Mandana Nikpour31, Alberta Hoi32 and Eric Morand33, 1Monash University, Clayton, Australia, 2Chiang Mai University, Chiang Mai, Thailand, 3Taichung Veterans General Hospital, Taichung, Taiwan, 4National University Health System (NUHS), Singapore, Singapore, 5National University Hospital, Singapore, Singapore, 6Hasan Sadikin Hospital, Jakarta Selatan, Indonesia, 7Chang Gung Memorial Hospital, Taoyuan, Taiwan, 8University of Santo Tomas, Manila, Philippines, 9University of Santo Tomas Hospital, Manila, Philippines, 10People's Hospital, Peking University Health Science Center, Beijing, China, 11Peking University Health Science Center, Beijing, China, 12University of Malaya, Kuala Lumpur, Malaysia, 13Division of Rheumatology, Department of Internal Medicine, Tokyo Women’s Medical University School of Medicine, Tokyo, Japan, 14The University of Melbourne, Melbourne, Australia, 15Peking University First Hospital, Beijing, China, 16Tan Tock Seng Hospital, Singapore, Singapore, 17Keio University, Tokyo, Japan, 18Keio University and Saitama Medical University, Tokyo, Japan, 19St Vincent's Hospital, Fitzroy, Australia, 20Hanyang University Medical Center, Seoul, Republic of Korea, 21Flinders Medical Centre, Adelaide, Australia, 22Liverpool Hospital, Sydney, Australia, 23North Shore Hospital, Auckland, New Zealand, 24Department of Rheumatology and Immunology, Singapore General Hospital, Singapore, Singapore, 25Teaching Hospital Kandy, Kandy, Sri Lanka, 26Greenlane Clinical Centre, Auckland, New Zealand, 27Middlemore Hospital, Auckland, New Zealand, 28University of the Philippines, Quezon City, Philippines, 29University of Occupational and Environmental Health, Kitakyusyu Fukuoka, Japan, 30The University of Hong Kong, Pok Fu Lam, Hong Kong, 31The University of Melbourne at St. Vincent's Hospital Melbourne, Melbourne, Australia, 32Monash Health, Melbourne, Australia, 33Monash University, Victoria; Department of Rheumatology, Monash Health, Melbourne, Australia

    Background/Purpose: Prevention of organ damage is one of the main treatment goals in systemic lupus erythematosus (SLE).The SLICC/ACR Damage Index (SDI) is used to quantify…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology